Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03113409 · ClinicalTrials.gov registry record · Phase 2
Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT03113409 is a Phase 2 study that was terminated before completion, run by New York State Psychiatric Institute. The registered enrollment target is 10 participants.
The verdict
NCT03113409, a Phase 2 study, was terminated before completion, sponsored by New York State Psychiatric Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The study will enroll 30 opioid-dependent participants into an open-label pilot outpatient study of methods to facilitate induction and stabilization onto XR-NTX. There will be three different methods of XR-NTX induction using increasing doses of oral naltrexone and buprenophine.
Interventions
- DRUG Buprenorphine
- DRUG Naltrexone
- DRUG Vivitrol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03113409
The ClinicalTrials.gov registry entry for NCT03113409 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Buprenorphine is the first listed.
NCT03113409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03113409 about?
NCT03113409 is a clinical study titled "Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol". The study will enroll 30 opioid-dependent participants into an open-label pilot outpatient study of methods to facilitate induction and stabilization onto XR-NTX. There will be three different methods of XR-NTX induction using increasing doses of oral naltrexone and buprenophine.
What is the current status of trial NCT03113409?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2017-06-01. Estimated completion is 2020-12-01.
What interventions are being tested in trial NCT03113409?
The interventions under investigation include: Buprenorphine (DRUG), Naltrexone (DRUG), Vivitrol (DRUG).
Who is sponsoring clinical trial NCT03113409?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.